---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003851"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:52:00.286230+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports Q3 net loss $3.2M; FDA agrees BMD endpoint for EB613 Phase 3

## Summary
- Net loss $3.2M ($0.07/share) vs $3.0M ($0.08/share) in Q3 2024; cash $16.6M through mid-Q3 2026.
- FDA agreed BMD as primary endpoint for single Phase 3 trial of EB613 (oral PTH) for osteoporosis; supports NDA.
- EB613 Phase 2 data showed significant BMD gains in younger postmenopausal women, presented at NAMS and ASBMR.
- Next-gen EB613 Phase 1 trial on track for late 2025; GLP-2 and OXM programs with OPKO advancing.

## SEC filing metadata
- accession: 0001178913-25-003851
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/0001178913-25-003851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/zk2534017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003851
- JSON: https://secwatch.observer/filing/0001178913-25-003851.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.